hat
Perampanel (vann anba Fycompa komès la) se yon dwòg antiepileptik devlope pa Eisai Co ki itilize nan adisyon nan dwòg lòt nan trete kriz malkadi ak jeneralize kriz tonik klonik pou moun ki gen plis pase 12 ane.Li te premye apwouve nan 2012 ak kòm nan 2016 wòl optimal li yo nan tretman an nan epilepsi relatif nan lòt dwòg pa t 'klè.Li te premye medikaman an antiepileptik nan klas la nan selektif anti-konpetitif antagonist nan AMPA reseptè.
eng
Perampanel (sold under the trade name Fycompa) is an antiepileptic drug developed by Eisai Co. that is used in addition to other drugs to treat partial seizures and generalized tonic-clonic seizures for people older than 12 years.It was first approved in 2012 and as of 2016 its optimal role in the treatment of epilepsy relative to other drugs was not clear.It was the first antiepileptic drug in the class of selective non-competitive antagonist of AMPA receptors.